Literature DB >> 3107027

Drug deprivation and reinforcement by diazepam in a dependent population.

H Cappell, U Busto, G Kay, C A Naranjo, E M Sellers, M Sanchez-Craig.   

Abstract

Individuals who were using therapeutic doses (approximately 15 mg diazepam or its equivalent daily) of a benzodiazepine persistently and wished to attempt to stop were recruited into a study offering a medically supported outpatient behavioral treatment with a goal of abstinence. All subjects received the same behavioral treatment that emphasized the development of strategies for coping with abstinence and alternatives to benzodiazepines as a coping mechanism. The goal of abstinence was to be achieved within approximately 8 weeks by means of gradual tapering of the daily dose. Some subjects (Group D, n = 23) were randomly assigned to a condition in which their dose was to be tapered on a regime of active diazepam. Others (Group P, n = 19) were switched to placebo at the first treatment session and "tapered" from this pharmacologically inert substitute for diazepam. Supplies of tablets of each preparation were provided by the experimenters, and subjects were specifically requested to use only those tablets. The principal dependent variable was "supplementation", or use of a benzodiazepine other than that specifically authorized by the therapist. Supplementation was detected by measures of plasma benzodiazepine levels as compared to levels predicted if there had been strict compliance with the therapeutic regime. These comparisons were made by two expert judges who were blind to the subjects' experimental assignment. Self-report of supplementation was also obtained. Plasma level determinations indicated a significantly greater frequency of supplementation (84% versus 33% of subjects) for subjects in Group P.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107027     DOI: 10.1007/bf00217055

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  22 in total

1.  Increase of "antianxiety" activity and tolerance of behavioral depression during chronic administration of oxazepam.

Authors:  D L Margules; L Stein
Journal:  Psychopharmacologia       Date:  1968

Review 2.  Benzodiazepines in general practice: time for a decision.

Authors:  J Catalan; D H Gath
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-11

3.  Patterns of benzodiazepine abuse and dependence.

Authors:  U Busto; E M Sellers; C A Naranjo; H D Cappell; M Sanchez-Craig; J Simpkins
Journal:  Br J Addict       Date:  1986-02

4.  Reinforcing properties of lorazepam in normal volunteers.

Authors:  H de Wit; C E Johanson; E H Uhlenhuth
Journal:  Drug Alcohol Depend       Date:  1984-01       Impact factor: 4.492

5.  Safety and efficacy of long-term diazepam therapy.

Authors:  C L Bowden; J G Fisher
Journal:  South Med J       Date:  1980-12       Impact factor: 0.954

6.  Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo.

Authors:  R R Griffiths; G E Bigelow; I Liebson; J E Kaliszak
Journal:  J Pharmacol Exp Ther       Date:  1980-12       Impact factor: 4.030

7.  Differential effects of diazepam and pentobarbital on mood and behavior.

Authors:  R R Griffiths; G E Bigelow; I Liebson
Journal:  Arch Gen Psychiatry       Date:  1983-08

Review 8.  Relative abuse liability of triazolam: experimental assessment in animals and humans.

Authors:  R R Griffiths; R J Lamb; N A Ator; J D Roache; J V Brady
Journal:  Neurosci Biobehav Rev       Date:  1985       Impact factor: 8.989

9.  Long-term diazepam therapy and clinical outcome.

Authors:  K Rickels; W G Case; R W Downing; A Winokur
Journal:  JAMA       Date:  1983-08-12       Impact factor: 56.272

10.  Drug preference and mood in humans: diazepam.

Authors:  C E Johanson; E H Uhlenhuth
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  4 in total

Review 1.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

2.  A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers.

Authors:  M Farré; M T Terán; J Camí
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

3.  Initial 3-month usage characteristics predict long-term use of benzodiazepines: an 8-year follow-up.

Authors:  Rolf van Hulten; K Bart Teeuw; Albert Bakker; Hubert G Leufkens
Journal:  Eur J Clin Pharmacol       Date:  2003-02-07       Impact factor: 2.953

Review 4.  Current benzodiazepine issues.

Authors:  J H Woods; G Winger
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.